A study protocol for the treatment of extranodal invasion or double-expression relapsed refractory diffuse large B-cell lymphoma with obritinib and decitabine combined with DICE

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045521

Enrollment

Unknown

Registered

2021-04-18

Start date

2021-04-18

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

extranodal invasion or double-expression relapsed refractory diffuse large B-cell lymphoma

Interventions

Treatment group:Aubrutinib + Decitabine +DICE

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged >=18 years; 2.Histologically diagnosed as diffuse large B-cell lymphoma with double expression of diffuse large B-cell lymphoma or imaging confirmed the presence of extranodal invasion; 3.Newly treated/relapsed and refractory patients; 4.Patients who have not previously received BTK inhibitors.

Exclusion criteria

Exclusion criteria: 1.There are active infections that are not controlled; 2.Combined with other malignant tumors; 3.Severe liver insufficiency; 4.Platelets are less than 30x10^9/L.

Design outcomes

Primary

Measure	Time frame
The overall response rate (ORR) during induction of remission;Progression-free survival;	—

Secondary

Measure	Time frame
Prognostic factors (such as age, sex, geriatric scale, chemotherapy intensity, IPI score, intermediate PET results, etc.);	—

Countries

China

Contacts

Public ContactHu Kai

Beijing Boren Hospital

huk@borenhospital.com+86 15010390336

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026